Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse

Ignacio Heras-Murillo, Diego Mañanes, Pablo Munné, Vanessa Núñez, Jessica Herrera, Mauro Catalá-Montoro, Maite Alvarez, Miguel A. del Pozo, Ignacio Melero, Stefanie K. Wculek () and David Sancho ()
Additional contact information
Ignacio Heras-Murillo: Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Diego Mañanes: Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Pablo Munné: Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Vanessa Núñez: Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Jessica Herrera: Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Mauro Catalá-Montoro: Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Maite Alvarez: CIMA Universidad de Navarra
Miguel A. del Pozo: Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Ignacio Melero: CIMA Universidad de Navarra
Stefanie K. Wculek: Centro Nacional de Investigaciones Cardiovasculares (CNIC)
David Sancho: Centro Nacional de Investigaciones Cardiovasculares (CNIC)

Nature Communications, 2025, vol. 16, issue 1, 1-17

Abstract: Abstract The potential of dendritic cell (DC) vaccination against cancer is not fully achieved. Little is known about the precise nature of the anti-cancer immune response triggered by different natural DC subsets and their relevance in preventing postsurgical tumor recurrence. Here, we use mouse splenic conventional DC1s (cDC1s) or cDC2s pulsed with tumor cell lysates to generate DC vaccines. cDC1-based vaccination induces a stronger effector and memory CD4+ and CD8+ anti-tumor T cell response, leading to a better control of tumors treated either therapeutically or prophylactically. Using an experimental model of tumor relapse, we show that adjuvant or neoadjuvant cDC1 vaccination improves anti-tumor immune memory, particularly by increasing the infiltrates of CD4+ tissue resident memory (Trm) and CD8+ memory T cells. This translates into complete prevention of tumor relapses. Moreover, elevated abundance of cDC1s positively correlates with CD4+ Trm presence, and both associate with enhanced survival in human breast cancer and melanoma. Our findings suggest that cDC1-based vaccination excels at immune memory induction and prevention of cancer recurrence.

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-58289-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58289-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-58289-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().